NFKB1 and liver disorder: Recent preclinical data have shown that supplementation with omentin-1 may inhibit the NF-κB and MAPK signaling pathways to maintain glucose and insulin metabolism in the context of metabolic dysfunction-associated steatotic liver disease.9